Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail

[1] Magura S(2009)Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial Drug Alcohol Depend 99 222-230

[2] Lee JD(2017)Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England Addiction 112 1408-1418

[3] Hershberger J(2015)Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder Addict Sci Clin Pract 10 2-407

[4] Joseph H(2018)Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system JAMA 75 405-88

[5] Marsch L(2009)Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey Drug Alcohol Depend 105 83-165

[6] Shropshire C(2007)Release from prison—a high risk of death for former inmates N Engl J Med 356 157-87

[7] Marsden J(2017)Death after release: matching to improve care delivery Corr Health Care 23 83-1242

[8] Stillwell G(2016)Extended-release naltrexone to prevent opioid relapse in criminal justice offenders N Eng J Med 374 1232-318

[9] Jones H(2017)Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a mulitcentre, open-label, randomized controlled trial Lancet 391 309-1849

[10] Cooper A(2018)Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial Addiction 113 1840-1014

[1] Magura S(2009)Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial Drug Alcohol Depend 99 222-230

[2] Lee JD(2017)Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England Addiction 112 1408-1418

[3] Hershberger J(2015)Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder Addict Sci Clin Pract 10 2-407

[4] Joseph H(2018)Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system JAMA 75 405-88

[5] Marsch L(2009)Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey Drug Alcohol Depend 105 83-165

[6] Shropshire C(2007)Release from prison—a high risk of death for former inmates N Engl J Med 356 157-87

[7] Marsden J(2017)Death after release: matching to improve care delivery Corr Health Care 23 83-1242

[8] Stillwell G(2016)Extended-release naltrexone to prevent opioid relapse in criminal justice offenders N Eng J Med 374 1232-318

[9] Jones H(2017)Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a mulitcentre, open-label, randomized controlled trial Lancet 391 309-1849

[10] Cooper A(2018)Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial Addiction 113 1840-1014